A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia

This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.

开始日期2026-04-01

申办/合作机构

Quetzal Therapeutics, LLC.

NCT07348107

/ Not yet recruiting临床1期IIT

A Phase 1 Study of ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-L1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.

This study is testing whether adding three drugs, All-Trans Retinoic Acid (ATRA), SDK002 (also called Arsenic Trioxide or ATO), and tislelizumab, to standard chemotherapy is safe for people with advanced pancreatic cancer. Advanced pancreatic cancer means the cancer has spread or cannot be removed with surgery. The study will also look at whether this treatment combination may help people live longer.
Participants will receive standard chemotherapy drugs, gemcitabine and nab-paclitaxel, together with ATRA, SDK002, and tislelizumab. ATRA is related to vitamin A and may affect how cancer cells grow. SDK002 is a drug used to treat sine cancers and may help other treatments work better. Tislelizumab is an immunotherapy drug, which helps the immune system recognize and attack cancer cells. This is a phase 1 study, which means the main goal is to test safety and side effects. All participants receive the same treatment, and both the study doctors and participants know which drugs are being given.

开始日期2026-02-15

申办/合作机构

Sdk Therapeutics, Inc.

NCT07296445

/ Not yet recruiting临床3期

LATITUDE - A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2-Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High-Risk, Acute Promyelocytic Leukemia

LATITUDE: A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2- Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High Risk, Acute Promyelocytic Leukemia
Rationale:
SDK Therapeutics is developing an oral formulation of arsenic trioxide (ATO) for the treatment of acute promyelocytic leukemia (APL). Patients with APL are usually treated with arsenic trioxide (ATO) through an IV along with all-trans retinoic acid (ATRA) taken by mouth. Receiving ATO through an IV requires patients with APL to go to the hospital a lot and get long treatments (sometimes every day over a year of treatment). This can be hard and uncomfortable. If ATO can be taken by mouth, it would be much easier for patients and their families.
Objective:
The main objective is to show that the body absorbs the same amount of ATO whether it's taken by mouth or through an IV. Other objectives include checking if ATO taken by mouth works just as well, causes fewer heart problems, is safe, and improves quality of life compared with ATO given through an IV.
Main trial endpoints:
The main endpoint being measured is how much ATO is in the blood after 5 doses. Another important endpoint is how many patients have no signs of cancer in their blood after 3 rounds of treatment.
Secondary trial endpoints:
Other things being measured include: whether patients stay cancer-free over 2 years; changes in heart rhythm; side effects and lab test results; how patients feel during treatment; how much of ATO is in the blood; and how often patients feel bothered by side effects.
Trial design:
This is an open-label study, meaning everyone knows which treatment they are getting. Patients will get 4 rounds of treatment, each lasting 8 weeks. After that, patients will have check-ups every 3 months to assess safety and disease status for a total of 2 years.
Trial population:
The study includes adults and teens (12 years and older) who have APL, are not high-risk, and have already finished the first part of their treatment (induction) with IV ATO and ATRA.
Interventions:
There are 3 groups in the study:
Cohort A: Takes 0.15 mg/kg Oral ATO for 3 rounds, then switches to 0.15 mg/kg IV ATO for part of the 4th round.
Cohort B: Takes 0.15 mg/kg IV ATO for 3 rounds, then switches to 0.15 mg/kg Oral ATO for part of the 4th round.
Cohort C: Takes 0.15 mg/kg Oral ATO for all 4 rounds.
All cohorts also take 45 mg/m2/day ATRA during certain weeks of each round. Doctors will assess efficacy by checking bone marrow samples before and during treatment to see if the cancer is gone. Special lab tests will be used to look for cancer cells. Safety will be assessed by checking for side effects using blood tests, heart tests, physical exams, and other health checks. Quality of life will be assessed by the patients who will fill out surveys about how they feel during treatment and how much the side effects bother them. The study will also look at how often patients need to go to the doctor or hospital; how treatment affects daily life and work; and how satisfied patients are with their treatment.

开始日期2026-01-01

申办/合作机构

Sdk Therapeutics, Inc.

100 项与三氧化二砷相关的临床结果

登录后查看更多信息

100 项与三氧化二砷相关的转化医学

登录后查看更多信息

100 项与三氧化二砷相关的专利（医药）

登录后查看更多信息

3,656

项与三氧化二砷相关的文献（医药）

2026-12-31·ANNALS OF MEDICINE

Acute leukemia during pregnancy: a single center experience with 23 cases, 2012–2022 and literature review

Review

作者: Zhao, Xie-Lan ; Chen, Cong ; Guo, Jiamin ; Fu, Xiao ; Gai, Dongzheng ; Liu, Yi ; Liu, Wei ; Rosen, Steven T. ; Chen, Fangping ; Zhang, Kai-Xuan

BACKGROUND AND OBJECTIVE:

Acute Leukemia (AL) diagnosed during pregnancy is uncommon, and the management of AL complicated by pregnancy is a poorly studied area that faces a therapeutic dilemma.

METHOD:

23 cases diagnosed with AL during pregnancy were collected from our center between 2012 and 2022. Additionally, we summarized 17 clinical studies on AL diagnosed during pregnancy.

RESULT:

Sixteen AML and seven ALL patients were diagnosed during pregnancy in our center; most patients diagnosed during the first or second trimester tended to receive chemotherapy after abortion. All patients diagnosed during the third trimester opted to defer therapy until after delivery. The rate of overall response rate (ORR) was 77.3%, which was found to be similar to that of the general population. A Short delay in initiating anti-leukemia treatment is not associated with a negative impact on prognosis. We conducted a meta-analysis of the literature, and the summary relative complete remission (CR) rate was 76.9% (95%CI 69.1-84.6%) (Random Effects Model I^2 = 66%, p <0.001). We included four Chinese studies comprising 135 participants for further analysis. For non-M3 AL patients, CR rate of the chemotherapy-first cohort was 63.6%, compared with 68.6% in the treatment-after-delivery or abortion cohort (p = 0.657). For M3 patients, the rate was 100 and 83.3%, respectively (p < 0.001).

CONCLUSION:

Our findings suggest that for non-M3 AL patients can sometimes be managed during pregnancy. For M3 patients, early treatment potentially yield favorable outcomes for both the mother and fetus, using ATRA-based regimens without arsenic trioxide (in the second and third trimester) or standard chemotherapy (in the second trimester) may be considered a treatment option.

2026-06-01·Current Research in Structural Biology

Acute arsenic trioxide inhibits the cardiac transient outward K+ current (Ito) and human Kv4.3/KChIP2c channels

Article

作者: Scior, Thomas ; Villa Diaz, Fernando ; López Martínez, Eduardo López ; Baez Castillo, Evili ; Moreno, Laura ; Ruíz Castelan, Jordan ; Ramírez Mata, Alberto ; Reyes Carmona, Sandra ; León Magdaleno, Jorge Samuel ; Sanchéz González, Juan ; Mancilla Simbro, Claudia ; Ríos Cano, Saúl ; Olea-Amezcua, Mónica A ; Herrera Salcedo, Fritzy D ; Villanueva Castillo, Arnulfo ; Pérez Cortes, Erwin ; Islas, Ángel A

Arsenic trioxide (As₂O₃) has been useful to treat acute promyelocytic leukaemia, as it inhibits the growth of various tumour cell lines and promotes apoptosis. However, its employment has been hindered by its cardiotoxic potential, since it prolongs cardiac repolarization. The transient outward K⁺ current (I_to) in the heart is a critical component of the early repolarization phase and a plateau of the cardiac action potential. While the molecular changes that explain the chronic effects of As₂O₃ on cardiac K⁺ currents are known, its immediate repercussions remain elusive. In the present work, we characterize the acute electrophysiological effects of As₂O₃ on the I_to in rat myocytes and on K_v4.3 channels co-expressed with their auxiliary subunit KChIP2c, which constitute the principal mediator of the I_to in the human ventricle. We found that this anion causes a reversible, voltage and concentration dependent inhibition (IC₅₀ ≈ 4 μM), reaching a maximum (38% block) at 100 μM, on both cell types. Bath perfusion of 4 μM As₂O₃ had no significant effect on the current kinetics or on the steady-state inactivation of the I_to, but it shifted the steady-state tail activation curve to more depolarized potentials. The development of As₂O₃ inhibition was fourfold faster upon intracellular administration. A ligand and structure-based computational strategy including pharmacophore and molecular docking was implemented to identify the stereochemistry of the ligand-protein binding.

2026-04-01·Materials Today Bio

The enhanced photothermal therapy against gastric cancer by mitochondria/STAT3-targeted nanoplatform with OXPHOS blocking

Article

作者: Wang, Xianwen ; Zhang, Gege ; Wu, Shuang ; Zheng, Yi ; Zou, Mi ; Zhang, Zhao ; Wang, Lingling ; Liang, Pingping ; Qiu, Jianda ; Wang, Wenbin ; Fang, Qiaojun ; Zhang, Yanling ; Sui, Yajie ; Huang, Qiong

Near-infrared (NIR) photothermal therapy (PTT) has provided an innovative modality for the ablation of gastric cancer (GC) with minimized damage to normal tissues. However, the upregulation of heat shock proteins (HSPs) and the abnormal vascularization at the tumor site, as well as the low specificity with the diffusional hindrance of therapeutic agents to cancer cells, severely hamper this mono-therapeutic strategy. To overcome these obstacles, we designed and prepared a mitochondria/STAT3-targeted nanoplatform (ATO/CR NPs), which is self-assembled by Drug Administration (FDA)-approved atorvaquinone (ATO) and NIR phototherapeutic agent CR to fight GC. The ATO/CR NPs exhibit enhanced PTT efficiency owing to the oxidative phosphorylation (OXPHOS) blocking in mitochondria for the downregulation of ATP and HSP based on ATO. More importantly, the ATO from ATO/CR NPs can also specifically target STAT3 in GC cells to restrain proliferation, inhibit angiogenesis, and promote apoptosis. Hence, the multimodal NIR ATO/CR NPs initiate accurate targeting of cancer cells, triggering serious mitochondrial dysfunction and cellular apoptosis to amplify the photo-ablation activity, which provides a promising strategy for GC treatment, warranting further preclinical exploration.

280

项与三氧化二砷相关的新闻（医药）

2026-04-10

·同写意

维健医药与雅各臣达成合作，加速首个中国香港自主研发新药ARSENOL®在内地开发与商业化

2026-04-09

·药通社

一款改良药，能卖130亿？

万邦德这家老牌公司，自3月以来频频被热议，市值猛涨，股价一个月内直接翻倍。据传引爆其行情的主要原因是，该公司旗下一款用于治疗阿尔兹海默症的改良新药，石杉碱甲控释片。这款药在业内争议不小，部分人对其持怀疑态度，也有部分人对这款药抱有很大期待。主要争议点之一是其销售预期。众所周知，中国是全球AD患者数量最多的国家。根据《中国AD报告2025》，2021年，中国AD及相关痴呆症患者近1700万，占全球总数的29.8%；死亡人数近49万人，占全球总数的25.2%。目前，临床常用的AD用药主要包括胆碱酯酶抑制剂、美金刚以及抗Aβ单抗。其中胆碱酯酶抑制剂主要包括多奈哌齐、卡巴拉汀、加兰他敏；抗Aβ单抗主要包括仑卡奈单抗、多奈单抗等。图源：东吴证券研究所而上述药物均存在弊端。胆碱酯酶抑制剂虽能改善症状，但也就仅能做到改善外显症状，不能延缓病情发展。而抗体药物，虽已被证实能延缓病程，但治疗费用高昂，同时临床应用门槛也极高且安全性风险较大。以仑卡奈单抗为代表，这是首个被证实能延缓疾病进程的抗 Aβ 单抗，但其年治疗费用高达18万元，远超国内患者支付能力。另外，这类药物需每两周静脉输注，且存在 ARIA（淀粉样蛋白相关影像学异常）风险——约 12.6%-30.7%的患者会出现脑水肿或脑微出血，需频繁 MRI 监测，对医疗资源配置要求极高。综上，目前市场上的常见用药，均有各自的局限。而理想的 AD 治疗药物应同时具备——延缓疾病进程的疾病修饰能力、良好的患者依从性、可负担的价格、以及广泛适用的安全性。那么在此情况下，万邦德的石杉碱甲控释片就被抬进了大众视野。石杉碱甲是从我国传统中草药蛇足石杉（千层塔）中分离得到的一种石松类生物碱，是一种高效、高选择性、可逆的乙酰胆碱酯酶抑制剂。自上世纪 80 年代被发现以来，石杉碱甲在我国临床上被应用于良性记忆障碍和阿尔茨海默症的治疗，已有超过30年的临床应用历史。诺贝尔奖获得者屠呦呦曾将其与青蒿素、三氧化二砷并列为中医药赠予世界的三个礼物，可见其重要性。目前国内的石杉碱甲制剂共三种，分别是片剂、胶囊剂和注射剂，属于上市时间很早，临床使用成熟但没有进行系统性研究的品种。 AD患者后期会失去清醒意识，从患者依从性上考虑，口服高于注射，而缓释片必定高于普通片。因此万邦德开发了石杉碱甲控释片，控释片具备四大核心优势：早前石杉碱甲只能天然提取，2013年万邦德成功实现了石杉碱甲的人工合成，也是从那时候起，万邦德就致力于研究石杉碱甲，目前已持有注射剂，缓释片、口服液等研究进度都很靠前。 2018年万邦德获得了石杉碱甲控释片的临床批件，目前正在进行3期临床。目标入组720例，截至今年2月已入组超100例。此品种已经入选为国家重大专项，因此业内关注度很高，而谈及市场，东吴证券甚至给出了130亿的销售预期。据东吴证券测算，基于GBD2021 数据，中国 AD 及相关痴呆患者总数为 1699 万人（2021 年）。考虑到人口老龄化，未来患者数将持续增长，但为保守测算，我们以当前患者数作为基数。但需考虑部分重度晚期患者可能因吞咽困难等无法口服给药，以及部分患者因合并症、禁忌症等原因不适合用药，参考临床实际，假设可覆盖患者总数的70%-80%，取中间值 75%。目标人群约 1300 万人。多奈哌齐等现有 ChEI 药物年治疗费用约 1000-1500 元（集采后价格），仑卡奈单抗年治疗费用约 18 万元，且需每两周住院输注，存在 ARIA 风险，临床使用门槛高。石杉碱甲控释片具备“一天一次+副作用更低+延缓疾病进展潜力”的差异化优势，作为改良型新药可给予显著溢价，作为口服制剂，使用便利性远高于生物制剂，但定价需考虑医保支付能力和患者自付能力。参考定价区间5000元/年-15000/年。综合以上分析，在中性假设下（目标人群 1300 万人、渗透率 10%、年治疗费用 10000元），石杉碱甲控释片的国内销售峰值约为130亿元。敏感性分析显示，在渗透率 5%-15%、年费用 5000-15000 元区间内，销售峰值介于32.5-292.5亿元之间。这还仅仅只是国内市场。一款改良药，单品年销售额能卖到130亿？石杉碱甲成分全部制剂目前的医院端销售仅3亿多，片剂销售额最高，也就才一亿多的市场。多奈哌齐和美金刚已经被集采，现今国内销售额已经不到5亿，加兰他敏销售额也不过3亿元。另两款已被证实能延缓疾病进程的仑卡奈单抗和多奈单抗，卫材年报显示，仑卡奈单抗2025年自然年收入为865亿日元，约合5.56亿美元，而据摩熵医药数据库显示，国内2025年仑卡奈单抗的销售额仅1.2亿，多奈单抗才两千多万。以仑卡奈单抗的年治疗费用折算一下，国内用了仑卡奈单抗的人群不到一千人，全球也就不到3万人。从上述产品销售情况来看，想在国内达到130亿貌似有点过于遥远。目前国内尚没有一款百亿单品，国内销售额最高的阿斯利康达格列净片的91亿，齐鲁的贝伐珠单抗77亿，离百亿甚至130亿都还有不小差距。如若石杉碱甲缓释片真的能做到，也只能直呼一句NB。除了缓释片，万邦德围绕石杉碱甲做了一系列布局，包括WP103石杉碱甲注射液（新生儿缺氧缺血性脑病）、WP107石杉碱甲口服溶液（重症肌无力），二者都是中美双报，且已经获得FDA孤儿药认定。图源：万邦德2025半年报参考：东吴证券医药研究、中国医药报、万邦德年报 ↓⭐关注药通社，洞见行业趋势↓ 投稿/企业合作/内容沟通：药通社总编—华籍美人（Ww_150525） *添加请注明备注及来意

2026-04-06

·生物世界

刘志红院士团队首次利用双靶点CAR-T成功治疗复发难治性AL淀粉样变性

编辑丨王多鱼排版丨水成文系统性轻链型（AL）淀粉样变性，是一种罕见的浆细胞异常增生疾病。异常浆细胞分泌的单克隆免疫球蛋白轻链错误折叠，沉积在肾脏、心脏等重要脏器，导致多器官功能衰竭，临床预后差。尽管近年来抗浆细胞治疗手段取得了进展，但仍有大量患者对现有的包括小分子药物、单抗和自体干细胞移植等治疗无效，或在治疗后复发。对于经历了多线治疗失败的复发/难治性 AL 淀粉样变性患者而言，传统治疗手段已无可奈何，临床上面临着巨大的困境，亟需研发新的治疗手段。 AL 淀粉样变性的致病核心是异常克隆的浆细胞，CD19 和 BCMA 在这些异常浆细胞中均有表达，是开发相关治疗药物的理想靶点。CAR-T 细胞疗法是一种新型精准细胞免疫治疗技术，可以通过改造 T 细胞表达相应靶点达到清除致病细胞的目的。对 AL 淀粉样变性这类疾病是理想的治疗方式。近年来，CAR-T 细胞疗法在临床研究中显示出对系统性红斑狼疮、系统性硬化症、特发性炎性肌病、重症肌无力、免疫介导的坏死性肌病等多种自身免疫性疾病具有良好的治疗效果。 2026 年 4 月 2 日，东部战区总医院国家肾脏疾病临床医学研究中心刘志红院士团队（东部战区总医院黄湘华、吴晓梅、陈文萃、徐维玮和复星凯瑞公司王文石为论文共同第一作者）在国际肾脏病学领域顶级期刊 Journal of the American Society of Nephrology 上发表题为：BCMA-CD19 dual-targeted CAR-T cell therapy for relapsed/refractory AL amyloidosis 的研究论文。该研究在国际上首次采用兼具抗 BCMA 和抗 CD19 活性的双靶点 CAR-T 细胞疗法治疗复发/难治性 AL 淀粉样变性患者，实现了 100% 血液学完全缓解率和 100% 的肾脏反应率；单细胞测序证实该疗法不仅能精准“剿灭”致病浆细胞，还能连根拔起驱动疾病复发的前体细胞和异常 B 细胞，实现了对致病克隆细胞的“斩草除根”，重建患者免疫微环境，为复发/难治性 AL 淀粉样变性患者的治疗带来了新曙光！双靶点 CAR-T 临床疗效显著研究团队创新的设计了同时表达 BCMA 和 CD19 的 CAR-T 细胞，其目的在于同时清除表达 BCMA 或 CD19 的浆细胞和 B 细胞。这种创新设计的 CAR-T 细胞不但可清除产生异常轻链的浆细胞，对浆细胞的前体细胞也同时予以清除，可诱导更深的血液学缓解，并为后续免疫重置创造条件。该研究纳入了 6 例复发/难治性 AL 淀粉样变性患者。主要入组标准为两线治疗失败，且均伴有主要器官受累的复发/难治性 AL 淀粉样变性患者。6 例患者均有肾脏受累，其中 1 例患者合并心脏受累。患者在清淋预处理后接受剂量为 0.3×106/公斤体重的 BCMA-CD19 双靶点 CAR-T 细胞治疗。血液学反应评估显示，6 名患者均实现血液学完全缓解（100%）。首次出现血液学反应的中位时间为 9 天（范围 4-14 天）。最佳血液学反应出现中位时间为 14 天（10-60 天），且所有患者均达到微小残留病变阴性。所有 6 例肾脏受累患者均达到肾脏反应。患者首次出现肾脏缓解的中位时间为 75 天（10-180 天）。出现最佳肾脏反应的中位时间为 180 天（60-450 天）。1 例心脏受累的患者也在治疗后第 28 天实现了心脏部分缓解，并在 CAR-T 治疗后 6 个月评估时维持心脏缓解。患者中位随访时间为 640 天（563-745 天），所有患者均存活。5 例患者在随访期间维持血液学完全缓解。1 例患者在治疗后 6 个月时出现血液学复发，在接受达雷妥尤单抗治疗后重新实现血液学完全缓解（患者 CAR-T 治疗前对达雷妥尤单抗耐药），并维持缓解状态。图2. BCMA-CD19双靶点CAR-T细胞治疗后CAR-T细胞动力学和血液学反应图3. BCMA-CD19双靶点CAR-T细胞治疗后的器官反应双靶点 CAR-T 治疗安全性良好随访期间，未观察到剂量限制性毒性。6 例患者中 2 例（33.3%）出现 1 级细胞因子释放综合征，未出现免疫效应细胞相关神经毒性综合征。CAR-T 治疗中最常见的不良事件为血液毒性和感染。研究共报告了 5 例 SAEs，2 例患者分别在 CAR-T 治疗后 3 周及 5 个月因肺炎住院，经抗感染治疗后好转出院。1 例患者因出现 3 级荨麻疹住院，接受糖皮质激素治疗后康复出院。1 例在治疗后第 115 天出现 2 级急性肾损伤，接受糖皮质激素治疗后好转出院。1 例患者在治疗后 15 个月被确诊为急性早幼粒白血病，采用全反式维甲酸联合三氧化二砷联合方案治疗后，评估达到完全缓解标准，该患者外周血单核细胞中未发现 CAR 或慢病毒序列的插入。双靶点 CAR-T 治疗全面重塑患者免疫特征在临床验证 BCMA-CD19 双靶点 CAR-T 治疗的疗效及安全性之外，研究还通过单细胞测序技术解析 CAR-T 治疗在免疫重建方面的独特优势。该疗法不仅实现了对克隆性浆细胞的深度清除，还有效清除了异常的 B 细胞和 CD19 阳性的干细胞样浆细胞，这些细胞是疾病复发的重要隐患。研究团队发现，患者的记忆 B 细胞已存在显著异常，表现为蛋白酶体介导的泛素依赖性蛋白分解代谢过程等通路上调。这些异常在 CAR-T 细胞输注后得到逆转，同时新产生的浆细胞内质网应激相关通路也明显下调。此外，CAR-T 细胞输注后外周血中整体 CD8+ T 细胞及 CD4+、CD8+ 效应 T 细胞均显著扩增，骨髓和外周血细胞毒性评分明显升高，提示 CAR-T 细胞治疗诱导机体产生抗克隆性浆细胞的免疫监视。重塑复发/难治性 AL 淀粉样变性患者治疗格局该研究为 BCMA-CD19 双靶点 CAR-T 细胞疗法在复发/难治性 AL 淀粉样变性患者中的安全性和有效性提供了证据。研究发现，BCMA-CD19 双靶点 CAR-T 细胞可产生快速且深度的血液学及器官反应，患者耐受性良好。该研究表明 BCMA-CD19 双靶点 CAR-T 细胞可能是复发/难治性 AL 淀粉样变性的潜在治疗选择，研究也为后续开展更大规模的临床研究提供了理论基础。论文链接： https://journals.lww.com/jasn/abstract/9900/bcma_cd19_dual_targeted_car_t_cell_therapy_for.976.aspx 设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群微信加群为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味

细胞疗法免疫疗法

100 项与三氧化二砷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02106	三氧化二砷	L01XX27	DB01169

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
急性早幼粒细胞白血病	美国	Cephalon, Inc.	2000-09-25

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性髓性白血病	临床3期	美国	Cephalon, Inc.	2007-10-01
急性髓性白血病	临床3期	加拿大	Cephalon, Inc.	2007-10-01
系统性红斑狼疮	临床2期	法国	Medsenic SAS	2013-07-01
小细胞癌	临床2期	美国	Cephalon, Inc.	2011-08-01
小细胞癌	临床2期	美国	Teva Pharmaceuticals USA, Inc.	2011-08-01
小细胞肺癌	临床2期	美国	Cephalon, Inc.	2011-08-01
小细胞肺癌	临床2期	美国	Teva Pharmaceuticals USA, Inc.	2011-08-01
转移性子宫内膜恶性肿瘤	临床2期	美国	Cephalon, Inc.	2010-03-01
胶质瘤	临床2期	美国	Cephalon, Inc.	2005-05-01
胶质瘤	临床2期	美国	CTI BioPharma Corp.	2005-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2025	N/A	急性早幼粒细胞白血病	26	ATRA+ATO/RIF+venetoclax	膚襯襯鏇醖遞選網淵壓(願積簾範齋糧選齋選鏇) = 鬱鬱衊醖築觸夢鑰鑰製製齋遞觸鹹醖網顧夢遞 (艱艱範築醖艱顧簾蓋鏇 ) 更多	积极	2025-12-06
ASH2025	N/A	急性早幼粒细胞白血病	64	ATRA + arsenic-based regimens	膚願積遞膚獵壓窪廠觸(膚醖衊鑰糧顧積鏇鬱醖) = 衊鹽窪壓餘餘繭窪選膚餘積蓋蓋選鏇鏇製餘憲 (獵構廠簾顧窪構鹹築遞 ) 更多	积极	2025-12-06
NCT02688140 (APOLLO, Pubmed \| J Clin Oncol)	临床3期	急性早幼粒细胞白血病一线	133	Arsenic Trioxide + All-Trans Retinoic Acid + Idarubicin	鹹繭簾憲鹽觸鑰簾夢選(繭窪遞憲簾淵築襯築築) = 糧膚顧鏇餘鹽鑰齋窪鬱鹹餘鬱夢繭積鬱繭獵構 (餘糧鑰獵鏇膚願膚蓋夢 )	积极	2025-10-10
NCT02688140 (APOLLO, Pubmed \| J Clin Oncol)	临床3期	急性早幼粒细胞白血病一线	133	Standard All-Trans Retinoic Acid + Anthracycline-Based Chemotherapy	鹹繭簾憲鹽觸鑰簾夢選(繭窪遞憲簾淵築襯築築) = 憲襯齋餘膚襯築積糧積鹹餘鬱夢繭積鬱繭獵構 (餘糧鑰獵鏇膚願膚蓋夢 )	积极	2025-10-10
PF538 (EHA2025)	N/A	急性早幼粒细胞白血病	156	Standard-dose ATO group	選選淵築艱齋壓齋窪夢(襯鹹積齋膚窪繭餘鏇憲) = 蓋夢願觸鏇膚膚糧餘鏇齋觸積襯廠築願網範網 (築齋獵夢餘獵獵蓋製製 ) 更多	-	2025-05-14
PF538 (EHA2025)	N/A	急性早幼粒细胞白血病	156	Low-dose ATO group	選選淵築艱齋壓齋窪夢(襯鹹積齋膚窪繭餘鏇憲) = 鏇膚衊選憲簾繭壓廠壓齋觸積襯廠築願網範網 (築齋獵夢餘獵獵蓋製製 ) 更多	-	2025-05-14
ASH2024	N/A	急性早幼粒细胞白血病	-	Standard-dose ATO (10mg IV daily for 28 days)	鑰繭夢鹹鏇淵衊製齋願(艱夢積鹹範艱製壓鬱構) = Patients receiving ATO treatment have a high rate of adverse events in both groups, reducing the total ATO dosage at induction treatment may reduce the adverse event rate and help patients achieve the same long-term survival. 積觸膚鏇繭鹹範範鹹鏇 (觸築壓餘獵淵製願壓夢 )	-	2024-12-09
ASH2024	N/A	急性早幼粒细胞白血病	-	Low-dose ATO (10mg IV daily for less than 28 days)		-	2024-12-09
ESMO_ASIA2024	N/A	急性早幼粒细胞白血病巩固	19	ATRA, ATO, DNR	餘鬱鹹衊醖糧醖鏇鏇衊(膚鑰壓壓選蓋鬱蓋夢觸) = 6 patients 顧範廠淵遞選鹹夢艱蓋 (繭顧衊餘齋鹹壓夢衊選 ) 更多	积极	2024-12-07
NCT01409161 (Pubmed \| Cancer)	临床2期	急性早幼粒细胞白血病	-	ATO-ATRA + Gemtuzumab ozogamicin	憲淵範繭醖鑰襯觸夢蓋(鹽積鹹膚構鬱構網廠淵) = 窪遞憲醖範顧選襯衊襯膚遞選鹽衊淵製築艱夢 (選獵壓衊獵繭壓憲選願, 88.9% ~ 97.7) 更多	积极	2024-11-25
NCT03503864 (Pubmed)	临床2期	高风险神经母细胞瘤	67	三氧化二砷+a modified N7 induction regimen	繭願願窪鹹淵餘鏇繭淵(憲網積觸襯積構鹽蓋廠) = 齋鬱選襯願糧鹽遞窪膚簾壓範淵窪選構壓積齋 (膚壓憲衊餘範願觸觸夢 ) 更多	积极	2024-10-02
EHA2024	N/A	急性早幼粒细胞白血病	-	ATRA-ATO	繭夢壓醖壓範淵廠鬱觸(觸鹽製壓獵鹽蓋鹹齋衊) = 33% of pts with leukocytosis developed bone pain poorly responsive to analgesics during leukocyte increase; this phenomenon was not observed in any of pts without leukocytosis (p=0.002) 範憲鹽簾鹽廠遞鏇淵艱 (壓構製鑰夢艱鑰觸蓋蓋 ) 更多	-	2024-05-14
EHA2024	N/A	急性早幼粒细胞白血病	-	Hydroxyurea		-	2024-05-14
ASH2023 人工标引	N/A	急性早幼粒细胞白血病一线	121	Oral-Arsenic Trioxide + All-Trans Retinoic Acid + ascorbic acid	窪選齋積膚餘窪鑰膚淵(築鹽築夢簾餘願觸獵鹹) = 糧壓餘蓋醖網廠範襯廠鹽簾餘醖鑰膚膚願鹹夢 (鏇鬱艱積鹹壓遞鑰淵築 ) 更多	积极	2023-12-09